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AbstrACt
Objective The study sought to compare angiographic and 
clinical outcomes of new-generation drug-eluting stents 
(DES) versus drug-coated balloon (DCB) in patients with 
coronary in-stent restenosis (ISR).
Design Meta-analysis using data from randomised trial 
found by searches on PubMed, the Cochrane Library,  
ClinicalTrials. gov and websites of major cardiovascular 
congresses.
setting Only randomised trials comparing DES with DCB 
were included.
Participants Patients with ISR in the included trials.
Interventions New-generation DES versus DCB.
Outcomes The angiographic and clinical outcomes 
including cardiac death, all-cause death, myocardial 
infarction, target lesion revascularisation (TLR), target 
vessel revascularisation (TVR), major adverse cardiac 
events (MACE) and stent thrombosis were investigated.
results Five trials including 913 patients were eligible 
and included. Pooled analysis in angiographic results 
identified that new-generation DES were associated with 
higher acute luminal gain (−0.31 mm, 95% CI −0.42 to 
−0.20, P<0.001) and lower per cent diameter stenosis 
(risk ratio (RR): 0.28, 95% CI 0.02 to 0.55, P=0.04). DES 
significantly reduced the risk of TLR (RR: 1.96, 95% CI 1.17 
to 3.28, P=0.01) compared with DCB; however, there was 
no statistical differences for MACE (RR: 1.21, 95% CI 0.67 
to 2.17, P=0.53), myocardial infarction (RR: 1.16, 95% CI 
0.55 to 2.48, P=0.69) and cardiac death (RR: 1.80, 95% CI 
0.60 to 5.39, P=0.29).
Conclusions Interventions with new-generation DES 
appear to be associated with significant reduction in per 
cent diameter stenosis and TLR at short-term follow-up, 
but had similar MACE, myocardial infarction and cardiac 
death for patients with coronary ISR compared with DCB. 
Appropriately powered studies with longer term follow-up 
are warranted to confirm these findings.
IntrODuCtIOn
Percutaneous coronary intervention with 
bare-metal stents (BMS) or drug-eluting stents 
(DES) has become one of the most frequently 
performed therapeutic procedures for 
coronary artery disease.1 The rate of in-stent 
restenosis (ISR) in clinical practice is nearly 
5% of patients treated with DES and 10% 
with BMS after 5 years.2 Given the number 
of patients undergoing a stent implantation, 
which amounts to approximately 1 000 000 
per annum in the USA, ISR will continue to 
remain an undesirable adverse outcome.3 
The management of patients with ISR 
remains challenging. Currently, the treat-
ment strategies for ISR mainly include cutting 
balloon angioplasty, plain old balloon angio-
plasty, drug-coated balloon (DCB) and DES.4 
Several recent studies have reported that both 
new-generation DES and DCB are superior 
to other interventional strategies for ISR.5–12 
Moreover, recent guidelines on myocardial 
revascularisation from the European Society 
of Cardiology recommend DCB and new-gen-
eration DES (class I, level A) for patients 
presenting with ISR.1 However, published 
literature comparing new-generation DES 
versus DCB in randomised settings conclude 
with diverging results.8 13–17 Additionally, 
these studies were constrained by the small 
sample size. To overcome these limitations, 
we performed a meta-analysis of randomised 
controlled trials (RCTs) to compare the clin-
ical and angiographic outcome results of 
strengths and limitations of this study
 ► Only randomised trials comparing drug-eluting 
stents with drug-coated balloon for patients with in-
stent restenosis (ISR) were allowed to be included in 
this meta-analysis.
 ► This study includes the largest patient population 
presenting with ISR.
 ► The results were based on the trial level and share 
the limitations of the original trials.
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new-generation DES versus DCB in patients with coro-
nary ISR.
MethODs
search strategy and selection criteria
Randomised trials comparing new-generation DES versus 
DCB for coronary ISR were searched in PubMed, the 
Cochrane Library and  ClinicalTrials. gov as well as the 
websites of major cardiovascular congresses. The subject 
keywords included coronary restenosis, drug-eluting 
balloon, paclitaxel-coated balloon, eluting stent(s) and 
randomised trial were applied to identify studies (online 
supplementary table 1). The last search was performed 
on 12 September 2016 by two independent investigators 
(J-ZC and Y-XZ). All studies comparing new-generation 
DES versus DCB irrespective of patients presenting with 
any types of ISR were included.
Data extraction and quality assessment
Two investigators (J-ZC and Y-XZ) independently screened 
the title and abstract of retrieved reports, reviewed the 
full articles of relevant citations in detail and extracted 
study characteristics, angiographic and longest available 
clinical outcomes. Any discrepancies or disagreements 
were settled by a third investigator (Y-JZ). The following 
variables were extracted from all eligible studies: enrol-
ment periods, patient characteristics, types of ISR, defini-
tion of ISR, follow-up duration, dual antiplatelet therapy 
and clinical and angiographic outcomes. The risk of bias 
for individual trials was assessed in accordance with the 
Cochrane Collaboration’s tool.18
Angiographic and clinical outcomes
The clinical outcomes of interest were cardiac death, 
all-cause death, myocardial infarction, target lesion revas-
cularisation (TLR), target vessel revascularisation (TVR), 
major adverse cardiac events (MACE) and stent throm-
bosis. TLR was defined as any repeated revascularisation 
involving the target lesion. MACE was defined as indi-
vidual trial. The angiographic endpoints were minimum 
lumen diameter (MLD), late lumen loss (LLL) and 
per cent diameter stenosis at 6 to 12 months. In-segment 
(the treated segment plus 5 mm proximal/distal margins) 
measurements were adopted for the analyses, but in-stent 
parameters was incorporated if in-segment data were not 
available.
Figure 1 Flow diagram of meta-analysis. DES, drug-eluting stents.
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statistical analysis
Risk ratio (RR) and mean differences with 95% CI were 
used as summary statistics. The Mantel-Haenszel fixed-ef-
fects model and inverse variance fixed-effects model were 
used for categorical variables and continuous variables, 
respectively. We calculated the I2 index and performed 
χ2 test to measure statistical heterogeneity among studies. 
An I2 >50% was considered as significant heterogeneity. 
A random-effects model was performed to calculate the 
risk estimation if a significant heterogeneity was detected. 
Sensitivity analyses were carried out by excluding the 
studies with a high level of risk of bias, and including only 
studies with a low proportion of missing data. Repeated 
analyses have been performed in the subsets of studies 
solely comparing paclitaxel-coated balloon versus everoli-
mus-eluting stents (EES), and patients with only BMS-ISR. 
The Egger’s linear regression tests were employed to test 
for funnel plot asymmetry at the P<0.10 level of signifi-
cance. However, the analysis for publication bias can only 
be tentative, as there is not enough power to support the 
test results due to the limited number of studies included. 
All the statistical analyses were performed using STATA 
V.13.0 and Review Manager V.5.3 (The Nordic Cochrane 
Centre, Copenhagen, Denmark).
results
Five trials with a total of 913 patients treated either with 
new-generation DES (n=414) or DCB (n=499) were 
eligible and included.8 13–17 The screening process is 
described in figure 1. The median sample size was 189 
(IQR 83–269). Only the prospective randomised Treat-
ment of In-Stent Restenosis (TIS) trial was single centre, 
and the others were multicentre. Patients enrolled were 
from Czech in the TIS trial, Spain in the Restenosis Intra-
stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs. 
Everolimus-eluting Stent (RIBS) IV and RIBS V trials, 
Belgium in the Safety and Efficacy of a Drug eIUting 
balloon in Coronary artery rEstenosis (SEDUCE) trial 
and Germany and Latvia in BIOLUX (Clinical perfor-
mance of the Pantera Lux paclitaxel coated balloon vs. 
the drug-eluting Orsiro hybrid stent system in patients 
with in-stent restenosis) RCT. All trials had a high risk 
of bias with respect to performance bias and the details 
of methodology in BIOLUX RCT trial were not avail-
able. The summary of risk judgement in individual trials 
is shown in online supplementary figure 1. The trial, 
patient and angiographic characteristics are summarised 
(table 1, online supplementary tables 2 and 3). Apart 
from 229 patients (25.1%) with mixed types of ISR in 
one trial,17 309 patients (33.9%) with DES-ISR were 
recruited in one trial,8 while 375 patients (41.0%) with 
BMS-ISR were recruited in three trials.14–16 The follow-up 
of patients ranged from 6 to 12 months angiographically, 
and from 12 to 36 months clinically.
tlr, tVr and MACe
TLR was reported in four trials including 777 
patients.8 13 16 17 The incidence of TLR in the DCB group 
(10.9%) was significantly higher than that in new-gener-
ation DES (5.2%) (RR: 1.96, 95% CI 1.17 to 3.28, P=0.01; 
I2=32%, P=0.22; figure 2A). TVR was not available in the 
BIOLUX RCT trial.17 There was no significant difference 
in the risk of TVR between DCB and DES (RR: 1.06, 
95% CI 0.48 to 2.34, P=0.89; I2=60%, P=0.06; figure 2B).
All but the SEDUCE trial reported the rates of MACE.16 
The rates of MACE between DCB (14.7%) and DES 
(9.0%) were comparable (RR: 1.21, 95% CI 0.67 to 2.17, 
P=0.53; I2=58%, P=0.07; figure 2C).
Cardiac death, all-cause death, myocardial infarction and 
stent thrombosis
Myocardial infarction, stent thrombosis and cardiac death 
were all available in five trials but all-cause death was not 
Table 1 Main characteristics of the included trials
Study Type Treatment arms
Sample 
size
Definition of 
ISR
Follow-up, months DAPT, months Definition of 
MACEAngiographic Clinical DCB DES
TIS BMS SP 
PCB
PE EES 68/68 ≥50% DS 12 12 3 6–12 Death, any MI 
and TVR
RIBS IV DES SP 
PCB
XP EES 154/155 ≥50% DS 9 12 3 12 Death, MI and 
TLR
SEDUCE BMS SP 
PCB
XP EES 25/25 >70% DS 9 12 n/a n/a n/a
RIBS V BMS SP 
PCB
XP EES 95/94 ≥50% DS 9 36 3 12 Death, MI and 
TLR
BIOLUX 
RCT
Both PL PCB Orsiro 
SES
157/72 n/a 6 12 n/a n/a Cardiac death, 
MI and TLR
BMS, bare-metal stents; DAPT, dual antiplatelet therapy; DCB, drug-coated balloon; DES, drug -eluting stents; DS, diameter stenosis; ISR, 
in-stent restenosis; MACE, major adverse cardiac events; MI, myocardial infarction; n/a, not available; PE EES, Promus Element everolimus-
eluting stents; PL PCB, Pantera Lux paclitaxel-coated balloon; RCT, randomised controlled trial; SEDUCE, Safety and Efficacy of a Drug 
eIUting balloon in Coronary artery rEstenosis; SES, sirolimus-eluting balloon; SP PCB, SeQuent Please paclitaxel-coated balloon; TLR, 
target lesion revascularisation; TVR, target vessel revascularisation; XP EES, Xience Prime everolimus-eluting stent.
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reported in the BIOLUX RCT trial.17 The pooled RR 
showed no significant differences in cardiac death (RR: 
1.80, 95% CI 0.60 to 5.39, P=0.29; I2=0%, P=0.92; figure 3A) 
and myocardial infarction (RR: 1.16, 95% CI 0.55 to 2.48, 
P=0.69; I2=0%, P=0.76; figure 3B) between the two arms, 
as well as all-cause death (RR: 1.50, 95% CI 0.62 to 3.62, 
P=0.37; I2=0%, P=0.55) and stent thrombosis (RR: 1.26, 
95% CI 0.39 to 4.04, P=0.70; I2=0%, P=0.75; figure 3C).
Angiographic endpoints
All five trials contributed to the angiographic follow-up 
results. Patients treated with new-generation DES had a 
significant increase of acute luminal gain (−0.31 mm, 95% CI 
−0.42 to −0.20, P<0.001; I2=52%, P=0.08; figure 4A) and 
reduction of per cent diameter stenosis (RR: 0.28, 95% CI 
0.02 to 0.55, P=0.04; I2=72%, P=0.006; figure 4B) compared 
with DCB.
A strong trend towards an increase in MLD (−0.23 mm, 
95% CI −0.47 to 0.01, P=0.06; I2=65%, P=0.02, figure 5A) 
was noted in the new-generation DES arm but this differ-
ence was not statistically significant compared with DCB.
All but the BIOLUX RCT trial reported the incidences 
of binary restenosis. Patients treated with new-generation 
DES were associated with a similar risk of binary reste-
nosis (RR: 1.25, 95% CI 0.57 to 2.75, P=0.58; I2=56%, 
P=0.08; figure 5B) and LLL (−0.06 mm, 95% CI −0.37 to 
0.25, P=0.71; I2=80%, P=0.0006; figure 5C) compared 
with DCB.
Publication bias and sensitivity analyses
No publication biases were found in all clinical and 
angiographic outcomes (online supplementary figure 
2). Sensitivity analyses suggested that DCB was associ-
ated with a high risk of MACE (RR: 1.57, 95% CI 1.04 to 
2.38, P=0.03; I2=19%, P=0.29) as well as an increase in in 
MLD (−0.29 mm, 95% CI −0.55 to −0.03, P=0.03; I2=64%, 
P=0.04) and binary restenosis (RR: 1.85, 95% CI 1.11 to 
3.10, P=0.02; I2=0%, P=0.99) while excluding the TIS trial 
which comes from a single centre. Detailed methodology 
in BIOLUX RCT trial was not available; however, MLD 
remained greater in the DES group when the BIOLUX 
RCT trial was omitted (−0.29 mm, 95% CI −0.55 to −0.04, 
Figure 2 Forest plots of risk ratios for target lesion revascularisation (TLR), target vessel revascularisation (TVR) and major 
adverse cardiac events (MACE). Size of data markers indicates weight of each trial included in the meta-analysis: (A) TLR, (B) 
TVR and (C) MACE. DCB, drug-coated balloon; DES, drug-eluting stents.
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P=0.03; I2=60%, P=0.06). In the setting of patients with 
BMS-ISR,13 15 16 no significant differences were found 
in DCB versus new-generation DES in all angiographic 
and clinical outcomes except for acute luminal gain 
(−0.39 mm, 95% CI −0.50 to −0.28, P<0.001; I2=0%, 
P=0.40). Patients treated exclusively with EES had signif-
icant low incidence of TLR (RR: 2.64, 95% CI 1.35 to 
5.18, P=0.005; I2=12%, P=0.32), increased acute luminal 
gain (−0.32 mm, 95% CI −0.47 to −0.17, P<0.001; I2=64%, 
P=0.04) and superior MLD (−0.29 mm, 95% CI −0.55 to 
−0.04, P=0.03; I2=60%, P=0.06). But no statistical differ-
ences in other clinical and angiographic outcomes were 
observed between the two groups.
DIsCussIOn
This meta-analysis included five randomised trials exam-
ining the angiographic and clinical outcomes of new-gen-
eration DES versus DCB in the treatment of any type 
of coronary ISR. The study, for the first time, showed 
that new-generation DES appears to be associated with 
an improved angiographic and clinical outcomes when 
compared with DCB irrespective of the types of ISR at 
short-term follow-up. The main findings are as follows: 
(1) new-generation DES were associated with a signifi-
cant reduction in TLR compared with DCB at the longest 
available follow-up; (2) there were no statistical differ-
ences in cardiac death, myocardial infarction and MACE 
between the two treatment strategies; (3) new-generation 
DES were associated with favourable angiographic results 
with significant increase in acute luminal gain and reduc-
tion in per cent diameter stenosis at 6-month to 12-month 
follow-up.
Previous meta-analyses
The choice of therapeutic methods for coronary ISR 
remains debatable. Several meta-analyses demonstrated 
that DCB and DES had comparable clinical and angio-
graphic results for patients with coronary ISR.5 19 20 
However, obvious pitfalls existed in these studies. First, 
Figure 3 Forest plots of risk ratios for myocardial infarction (MI), cardiac death and stent thrombosis. Size of data markers 
indicates weight of each trial: (A) MI, (B) cardiac death, (C) stent thrombosis. DCB, drug-coated balloon; DES, drug-eluting 
stents.
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Mamuti et al20 combined new-generation DES and 
first-generation DES in the same group, whereas cumu-
lative evidence has illustrated the difference in clinical 
performance of different-generation DES.21 Liou et al 
demonstrated no superiority of the new-generation DES 
over DCB but their analysis included four observational 
studies in which an inequality of baseline characteristics 
was observed.19 A further limitation of this meta-analysis 
was the small number of randomised patients (n=548 
from three RCTs).19 Additionally, in a Bayesian network 
meta-analysis comparing the performance of all thera-
peutic treatments for ISR, EES was considered as optimal 
strategy with pronounced improvements in clinical 
outcomes.6 However, the effect was mainly derived from 
indirect comparison.5 In the present meta-analysis, we, for 
the first time, included only randomised trials of new-gen-
eration DES in comparison with DCB, so the possibility of 
confounders influencing estimates for various endpoints 
is less likely. Furthermore, this meta-analysis included the 
largest number of patients with ISR to date and demon-
strated that contemporary DES with improved design 
were associated with favourable outcomes and a lower risk 
of reintervention at midterm follow-up, compared with 
DCB.
Angiographic and clinical outcomes
Compared with DCB, new-generation DES were related 
to favourable prognosis for coronary ISR with superior 
angiographic outcomes and reduced TLR. The advan-
tages of new-generation DES comprised of persistent 
radial strength which prevents acute or subacute prolapse 
of the disrupted plaque and elastic recoil of the vessel 
wall, sufficient antiproliferative drugs and subsequent 
excellent neointimal hyperplasia inhibition compared 
with DCB.8 22 Interestingly, the rate of recurrent binary 
restenosis was similar in two groups. The difference of 
TLR was possibly related to the fact that presence of an 
existing additional stent layer in the DES group discour-
aged the operator from repeat intervention.
Although one may argue that DES add one more stent 
layer in the finite lesion segment, 80–100 µm of lumen 
loss due to the implants seems negligible when consid-
ering that new-generation DES assumes less reinter-
vention. Although one may express concern regarding 
the long-term safety of stent implantation, studies have 
shown that the vascular inflammatory response with the 
thin-strut platform profile and also its biocompatibility or 
biodegradable polymer is extremely low.4 21 23 The present 
study, however, remains limited by its small sample size 
and short periods of follow-up. By virtue of previously 
published literature, it is reasonable to assume that the 
short-term (less than 1 year) benefit of new-generation 
DES will remain consistent.
In the RIBS V trial,13 14 the authors have observed one 
TLR event in the EES group and two in the DCB group 
from 1 to 3 years. In the RESTENT-ISR (Prospective 
Randomised Comparison of Clinical and Angiographic 
Outcomes Between Everolimus-eluting vs Zotarolim-
us-eluting Stents for Treatment of Coronary Restenosis in 
Drug-Eluting Stents: Intravascular Ultrasound Volumetric 
Analysis) trial, Hong et al reported an approximate rate of 
6.0% in late (>1 year) TLR in patients with ISR treated with 
EES and zotarolimus-eluting stents,24 similar to several 
subgroups from all-comers study.25 26 Similarly, rates of 
TLR after 1 year of DCB angioplasty were varied between 
Figure 4 Forest plots of risk ratios for acute lumen gain and per cent diameter stenosis. Size of data markers indicates weight 
of each trial included in the meta-analysis: (A) acute lumen gain and (B) per cent diameter stenosis (DS). DCB, drug-coated 
balloon; DES, drug-eluting stents.
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0% and 10%.6 7 11 12 The Intracoronary Stenting and Angio-
graphic Results: Drug Eluting Stent In-Stent Restenosis: 3 
Treatment Approaches (ISAR-DESIRE 3) and PEPCAD 
China ISR (A Prospective, Multicenter, Randomised Trial 
of Paclitaxel-Coated versus Paclitaxel-Eluting Stent for 
the Treatment of Drug-Eluting Stent In-Stent Restenosis) 
trials have shown a late mortality benefit of DCB treat-
ment versus first-generation DES treatment on longer 
follow-up. On the other hand, there were similar deaths 
in the EES group and DCB group from 1 to 3 years in 
the RIBS V trial. Thus, any potential long-term benefit 
of DCB compared with additional new-generation DES 
implantation remains unproven.27
The studies included in this meta-analysis have several 
differences. First, The RIBS IV trial contributed signifi-
cantly in the endpoint of TLR in favour of DES on the 
basis of our sensitivity analysis.11 The RIBS IV and RIBS 
V trials, which account for nearly 64% of studied patient 
populations in this meta-analysis, allowed acute predila-
tation residual stenosis of up to 50% before DCB appli-
cation. This is in strong opposition to what is accepted 
by most high-volume DCB centres and published as the 
German Consensus Recommendations.10 Moreover, our 
study presented high heterogeneities in the majority of 
angiographic and clinical outcomes, which were mainly 
driven by the TIS trial.15 The TIS trial had small sample 
size and extensive inclusion/exclusion criteria.28 29 
Furthermore, the use of scoring balloons and implanta-
tion of another bail-out stent were more common in TIS 
trial, which may have a potential role in improving the 
antiproliferation potency of DCB.30 Further researches 
with a careful follow-up protocol and large sample size 
should be performed to provide more confirmative 
information.
Future perspectives
Both new-generation DES and DCB for the treatment 
of ISR are on the same class I (A) recommendation in 
the latest European Society of Cardiology guideline on 
myocardial revascularisation.1 However, our meta-anal-
ysis suggests that new-generation DES represent a supe-
rior treatment strategy with similar safety and improved 
angiographic and clinical efficacy at short-term follow-up. 
Nevertheless, concerns remain about multilayers of 
Figure 5 Forest plot of risk ratios for minimum lumen diameter (MLD), binary restenosis and late lumen loss (LLL). Size of data 
markers indicates weight of each trial included in the meta-analysis: (A) MLD, (B) binary restenosis and (C) LLL. DCB, drug-
coated balloon; DES, drug-eluting stents.
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metal stents in the vessel wall which may entail difficulty 
in further treatments and an inherent poorer clinical 
prognosis.31 Similarly, for patients with intolerable long-
term dual antiplatelet therapy or high risk of bleeding, 
DCB may be more suitable. Bioresorbable scaffold (BRS) 
may be an alternative treatment choice in the future.32 33 
The ongoing AbsorbISR (Absorb Bioresorbable Scaffold 
vs Drug Coated Balloon for Treatment of In-Stent-Rest-
enosis, NCT02474485) trial comparing bioresorbable 
vascular scaffold with DCB to treat ISR will shed light in 
terms of clinical utility of BRS for coronary ISR. Finally, 
further refinements in DCB technology and auxiliary 
strategies,34 35 such as use of scoring balloon before 
DCB,30 are warranted.
limitations
The following potential limitations of the present study 
are acknowledged. First, the results were based on the 
trial level and share the limitations of the original trials. 
Specially, the clinical outcomes of TLR, TVR and MACE 
were only reported in four trials, respectively, which may, 
in some degree, affect the outcomes of this meta-anal-
ysis. Second, the studied DCB group included Sequent 
Please and Pantera Lux paclitaxel-eluting balloons, which 
have different coatings design, as well as the implemental 
methods of DCB in individual trials.10 Thirdly, the defi-
nitions of clinical and angiographic parameters were not 
identical in some studies. Finally, in light of the fairly 
highly selected criteria in our study, only a total of 913 
patients were enrolled. However, our study demonstrates 
the largest patient population presenting with ISR and is 
likely to remain the most powerful evidence base for eval-
uation of DCB versus new-generation DES.
COnClusIOns
New-generation DES seems an acceptable treatment strategy 
with comparable safety and favourable angiographic and 
clinical efficacy compared with DCB for coronary ISR at 
short-term follow-up. Further larger-scale randomised trials 
with longer term follow-up are warranted.
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